Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTrufin Plc Regulatory News (TRU)

Share Price Information for Trufin Plc (TRU)

Share Price is delayed by 15 minutes
Get Live Data
134.00    0.00 (0.00%)
Bid:
133.00
Ask:
135.00
Spread: 2.00 (1.504%)
Market Cap: £126.23m
TRU Live PriceLast checked at - London Stock Exchange

Intraday Trufin Plc Share Chart

Trading Statement

6 Jan 2025 07:00

RNS Number : 1636S
TruFin PLC
06 January 2025
 

6 January 2025

 

TruFin plc("TruFin" or the "Group")

 

Trading Update

 

TruFin is pleased to announce that it expects its adjusted profit before tax1 ("PBT") to be significantly ahead of market expectations resulting in its first full year profit - a year earlier than forecast. For the 12 months ended 31 December 2024, PBT is now expected to be more than £0.5m (FY23: £(6.6)m) with adjusted EBITDA1 also expected to be significantly ahead of prior expectations at more than £7.0m, representing a year-on-year improvement in excess of £10m (FY23: £(3.5)m).

 

Group revenue is expected to be approximately £54.0m. This represents growth in excess of 197% (FY23: £18.1m).

 

The significantly better than expected financial performance has been driven by exceptional year-end performances from Balatro and Abiotic Factor - two of Playstack Limited's ("Playstack") games launched during 2024. Balatro's recent award wins in three categories at the Game Awards: 'Best Independent Game', 'Best Mobile Game' and 'Best Debut Indie Game', helped to significantly boost sales of the game during December.

 

Oxygen Finance Group Limited ("Oxygen") grew revenues with metronomic consistency in 2024, resulting in growth of 21% to no less than £7.5m (FY23: £6.2m). EBITDA grew 65% at no less than £2.1m (FY23: £1.3m). With four new Early Payment ("EP") client wins during 2024 and all four EP clients up for renewal during 2024 contracting for further five year terms, Oxygen ended the year with a record 62 EP clients.

 

Satago Financial Solutions Limited ("Satago") aggressively realigned its cost base during 2024 and is in advanced talks with several Tier-1 Banks and other potential clients. Having lost its contract with a Tier-1 Bank in July 2024, revenues for 2024 are expected to be no less than £2.4m (FY23: £3.8m). Loss before tax is expected to be no more than £(4.9)m (FY23: £(4.2)m). Satago has a fully costed and funded plan to achieve cash flow breakeven in the next 18 months.

 

Cash at year end is no less than £14.0m, of which unrestricted cash is no less than £12.5m. The Group has had an exceptional year and remains focused on realising value for shareholders.

 

James van den Bergh, Chief Executive Officer, commented:

 

"What a year for the Group. A year of many firsts.

This is the first time we have grown revenues by more than 190%. It is the first year we have recorded an EBITDA profit and the first year we have achieved a profit before tax - a year ahead of schedule.

Most importantly our newly minted profitability status is not a one off. Although we expect 2025 to be a year of consolidation, we will maintain our disciplined approach to allocating internal resources and expect the Group to grow all the profitability lines in 2025 and beyond.

After years of considered investment and planning, Playstack has come of age. The standout financial achievements this year are the remarkable revenue growth of over 440% with an exceptional EBITDA growth of over 2,000%.

These achievements would not have been possible without our extremely disciplined and careful approach to building a robust and scalable games publisher.

The success of Balatro should not be underestimated and it has been a joy to watch it build throughout the year. However, it is important to also praise the team for the exceptional performances of Abiotic Factor and The Rise of the Golden Idol. Success breeds success and with eight game releases due in 2025 and a growing pipeline of game releases for 2026, we are closer than ever to monetising shareholder value from Playstack.

Following Vicki Sloane's appointment as Chief Executive Officer of Oxygen it is very pleasing to see her team deliver new highs across the board. Notably, this is the first year that shareholders have enjoyed the benefits of Oxygen's inherent operational gearing. With more than 82% of the next five years' Early Payment revenues already contracted, shareholders have much to look forward to. 

Satago's loss of a Tier-1 Bank contract in July 2024 was an enormous shock. However, the team have realigned the cost base and are poised for a year of growth, with a clear business plan to achieve cash breakeven within 18 months. We are focused on rebuilding shareholder value and the recent share recapitalisation at Satago is the first step to achieving that.

I look forward to providing a more detailed update during TruFin's annual results statement. In the meantime, I would like to again thank our shareholders for their ongoing support. This has been an exceptional year, and it is safe to say the Group has never been better positioned to deliver further shareholder value."

Notes

1 profit or loss adjusted to remove share-based payment charges

 

 

The information contained within this Announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No.596/2014 as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019. By the publication of this Announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain. The person responsible for arranging for the release of this Announcement on behalf of the Company is Pav Subramaniam.

For further information, please contact:

TruFin plcJames van den Bergh, Chief Executive OfficerKam Bansil, Investor Relations

0203 743 134007779 229508

Liberum Capital Limited (Nominated Adviser and Corporate broker)Chris ClarkeEdward Thomas

 

0203 100 2000

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDZGGMGKZGKZZ
Date   Source Headline
20th Dec 20239:40 amRNSHolding(s) in Company
14th Dec 20237:00 amRNSAppointment of INED to the Board of Oxygen
21st Nov 20237:00 amRNSPlaystack enters into LoI for sale of Interact
9th Nov 20237:00 amRNSOxygen Finance acquisition of bidstats.uk
18th Oct 20234:19 pmRNSHolding(s) in Company
5th Oct 20237:00 amRNSSale of Majority Holding in Vertus
29th Sep 20237:00 amRNSHalf-year Report
28th Sep 202312:07 pmRNSResult of AGM
14th Sep 20238:00 amRNSPlaystack releases award-winning game - AK-xolotl
29th Aug 20236:19 pmRNSNotice of AGM
21st Aug 20237:00 amRNSNon-Binding Offer for Vertus
28th Jul 20237:00 amRNSGrant of Share Awards under LTIP
18th Jul 20238:59 amRNSHolding(s) in Company
18th Jul 20238:58 amRNSHolding(s) in Company
18th Jul 20238:55 amRNSHolding(s) in Company
10th Jul 202312:03 pmRNSResult of GM and Result of Placing and Open Offer
23rd Jun 20237:00 amRNSResult of Placing and Notice of General Meeting
22nd Jun 20234:45 pmRNSProposed Placing and Open Offer
18th May 20233:04 pmRNSHolding(s) in Company
26th Apr 20237:00 amRNSOxygen Finance secures six Early Payment contracts
15th Mar 20237:00 amRNSFinal Results for the year ended 31 December 2022
28th Feb 20235:43 pmRNSHolding(s) in Company
23rd Jan 20237:00 amRNSStatement re Satago
20th Jan 20237:00 amRNSStatement regarding Satago and Trading Update
22nd Dec 20227:00 amRNSRejected Indicative Offer for Oxygen
15th Nov 20227:00 amRNSOxygen surpasses £1b in early payment provision
3rd Nov 20227:00 amRNSPlaystack releases new console game
20th Oct 20227:00 amRNSSatago signs agreement with Sage
10th Oct 20227:00 amRNSNotice of Capital Markets Day
30th Sep 20227:00 amRNSPDMR Notification
20th Sep 20227:00 amRNSInterim Results
12th Sep 20227:00 amRNSNotice of Capital Markets Day
25th Aug 20229:37 amRNSHolding(s) in Company
29th Jul 20229:00 amRNSPrice Monitoring Extension
29th Jul 20227:00 amRNSSatago signs commercial agreement with Lloyds
1st Jul 20227:00 amRNSHolding(s) in Company
9th Jun 20227:00 amRNSSatago partnership with Sage and Lloyds
7th Jun 202211:19 amRNSResult of AGM
6th Jun 20227:00 amRNSStatement re Playstack
4th May 20225:58 pmRNSNotice of AGM
29th Apr 20227:00 amRNSFinal Results For The Year Ended 31 December 2021
19th Apr 202212:04 pmRNSHolding(s) in Company
12th Apr 20225:53 pmRNSHolding(s) in Company
11th Apr 202210:18 amRNSResult of GM and Result of Placing and Open Offer
23rd Mar 20227:00 amRNSResult of Placing and Notice of General Meeting
22nd Mar 20224:51 pmRNSProposed Placing and Open Offer
9th Mar 20227:00 amRNSStatement re Satago
22nd Feb 20222:04 pmRNSVesting of JSOP Founder Awards
16th Feb 20227:00 amRNSDirectorate Change and Relationship Agreement
10th Dec 20217:00 amRNSStatement regarding Satago and Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.